AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Sulfamethoxypyridazine belongs to the sulfonamide class of antibiotics, which inhibit the growth and replication of susceptible bacteria by interfering with the synthesis of folic acid, a crucial component for bacterial survival. It is effective against a wide range of gram-positive and gram-negative bacteria.
Veterinary Use: Sulfamethoxypyridazine is commonly used in veterinary medicine to treat bacterial infections in livestock, poultry, and other animals. It may be administered orally or added to animal feed or drinking water to control or prevent infections caused by susceptible bacteria.
Indications: Sulfamethoxypyridazine may be used to treat various bacterial infections in animals, including respiratory tract infections, gastrointestinal infections, urinary tract infections, reproductive tract infections, and systemic infections. It is often used in combination with other antibiotics for broad-spectrum antibacterial coverage.
Dosage and Administration: The dosage of sulfamethoxypyridazine in animals varies depending on the species, age, weight, and severity of the infection. It is essential to follow the veterinarian's instructions and administer the medication according to the prescribed dosage regimen to ensure optimal efficacy and safety.
Adverse Effects: Like other sulfonamide antibiotics, sulfamethoxypyridazine may cause adverse effects in animals, including gastrointestinal disturbances such as nausea, vomiting, diarrhea, and decreased appetite. Allergic reactions and skin sensitivities may also occur, although they are less common. In rare cases, sulfonamide antibiotics may cause serious adverse effects such as hematologic abnormalities, liver or kidney toxicity, or allergic reactions leading to anaphylaxis.
Drug Interactions: Sulfamethoxypyridazine may interact with other medications or compounds, including other antibiotics, diuretics, anticoagulants, and certain nonsteroidal anti-inflammatory drugs (NSAIDs). It is essential to consult with a veterinarian before administering sulfamethoxypyridazine concurrently with other medications to avoid potential interactions or adverse effects.
Withdrawal Period: In food-producing animals, such as livestock and poultry, there may be specific withdrawal periods mandated to ensure that residues of sulfamethoxypyridazine or its metabolites are not present in animal-derived products intended for human consumption. Compliance with withdrawal periods is necessary to prevent potential health risks associated with drug residues in food products.
Regulatory Considerations: The use of sulfamethoxypyridazine in animals is subject to regulations and guidelines established by regulatory authorities, veterinary associations, and industry organizations to promote the responsible use of antibiotics and minimize the development of antimicrobial resistance.
Consultation with Veterinarian: Owners of animals requiring treatment with sulfamethoxypyridazine should consult with a qualified veterinarian for proper diagnosis, treatment recommendations, and monitoring of the animal's response to therapy. Veterinarians can provide guidance on the appropriate use of sulfamethoxypyridazine and ensure the safety and welfare of the animals under their care.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 1.4 | 0.6 | 1.33 |
| Allergic Rhinitis (Hay Fever) | 0.9 | 1.1 | -0.22 |
| Allergies | 0.7 | 1.1 | -0.57 |
| Allergy to milk products | 0.6 | 0.6 | 0 |
| Alzheimer's disease | 0.9 | 1.9 | -1.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | |
| Ankylosing spondylitis | 0.9 | 0.3 | 2 |
| Anorexia Nervosa | 0.6 | 1.2 | -1 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 1.9 | 1.4 | 0.36 |
| Atherosclerosis | 0.9 | 0.1 | 8 |
| Atrial fibrillation | 1.8 | 0.6 | 2 |
| Autism | 1.6 | 2.3 | -0.44 |
| Autoimmune Disease | 0.6 | 0.3 | 1 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.3 | 0.3 | 0 |
| Brain Trauma | 0.6 | 0.6 | 0 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.9 | 0.6 | 0.5 |
| Celiac Disease | 1.1 | 0.6 | 0.83 |
| Cerebral Palsy | 0.9 | 0.3 | 2 |
| Chronic Fatigue Syndrome | 0.9 | 1.6 | -0.78 |
| Chronic Kidney Disease | 0.3 | 0.3 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.6 | 1 |
| Chronic Urticaria (Hives) | 0.3 | 0.4 | -0.33 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| Cognitive Function | 0.9 | 0.6 | 0.5 |
| Colorectal Cancer | 2.3 | 1.2 | 0.92 |
| Constipation | 0.4 | 0.4 | |
| Coronary artery disease | 0.6 | 1 | -0.67 |
| COVID-19 | 1.5 | 2.8 | -0.87 |
| Crohn's Disease | 1.6 | 1.3 | 0.23 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.1 | -1.1 | |
| deep vein thrombosis | 0.7 | 0.6 | 0.17 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 2.2 | 1.7 | 0.29 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.3 | 2.1 | -6 |
| Endometriosis | 1.2 | 0.3 | 3 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.2 | 0.6 | 1 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 0.3 | 0.8 | -1.67 |
| Functional constipation / chronic idiopathic constipation | 1.6 | 1.2 | 0.33 |
| gallstone disease (gsd) | 0.4 | 0.3 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 0.9 | 1.2 | -0.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.6 | 1.2 | -1 |
| Gulf War Syndrome | 0.6 | 0.7 | -0.17 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 0.9 | 0.6 | 0.5 |
| Heart Failure | 0.9 | 0.3 | 2 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hyperglycemia | 0.6 | 0.6 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 0.9 | 2.1 | -1.33 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 0.6 | 0.3 | 1 |
| IgA nephropathy (IgAN) | 0.6 | 0.3 | 1 |
| Inflammatory Bowel Disease | 2 | 2.4 | -0.2 |
| Insomnia | 1.5 | 0.9 | 0.67 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.3 | 0.6 | -1 |
| Irritable Bowel Syndrome | 1.2 | 1.3 | -0.08 |
| ischemic stroke | 0.9 | 0.6 | 0.5 |
| Liver Cirrhosis | 2.4 | 1.2 | 1 |
| Long COVID | 1.5 | 1.7 | -0.13 |
| Low bone mineral density | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.3 | 0.8 | -1.67 |
| ME/CFS without IBS | 0.3 | 0.6 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.9 | |
| Metabolic Syndrome | 1.5 | 2.2 | -0.47 |
| Mood Disorders | 2.1 | 1.7 | 0.24 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 1.3 | 1.6 | -0.23 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.5 | -1.5 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 1.2 | 2.7 | -1.25 |
| obsessive-compulsive disorder | 1.1 | 1.4 | -0.27 |
| Osteoarthritis | 0.6 | 0.9 | -0.5 |
| Osteoporosis | 0.3 | 0.6 | -1 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2.1 | 1.9 | 0.11 |
| Polycystic ovary syndrome | 1.6 | 0.9 | 0.78 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.6 | 0.3 | 1 |
| Psoriasis | 0.9 | 0.6 | 0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 1.3 | -0.08 |
| Rosacea | 0.3 | 0.3 | 0 |
| Schizophrenia | 1.7 | 0.9 | 0.89 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 0.3 | 1.4 | -3.67 |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.9 | -0.5 |
| Systemic Lupus Erythematosus | 1.2 | 0.3 | 3 |
| Tic Disorder | 0.4 | 0.3 | 0.33 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.4 | 1.5 | -0.07 |
| Type 2 Diabetes | 2.2 | 2.2 | 0 |
| Ulcerative colitis | 1.4 | 1.4 | 0 |
| Unhealthy Ageing | 1.4 | 0.6 | 1.33 |
| Vitiligo | 1.2 | 0.5 | 1.4 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
